Peptide-MHC complexes assembled following multiple pathways: An opportunity for the design of vaccines and therapeutic molecules

Human Immunology

Volumn 54, Issue 2, 1997, Pages 137-147

  Corradin, Giampietro ^a   Demotz, Stéphane ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; SYNTHETIC PEPTIDE; VACCINE; VIRUS PROTEIN;

ANTIGEN PRESENTATION; B CELL LYMPHOMA; COMPLEX FORMATION; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEASLES VIRUS; PRIORITY JOURNAL; REVIEW;

ANTIGEN PRESENTATION; ANTIGENS; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MEASLES VIRUS; MODELS, IMMUNOLOGICAL; PEPTIDES; T-LYMPHOCYTES; VACCINES; VIRAL PROTEINS;

EID: 0030752577     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(97)00080-3     Document Type: Review

References (106)

1. Garcia CK, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PP, Teyton L, Wilson IA: An αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 274:209, 1996.
2. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddisson WE, Wiley DC: Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384: 134, 1996.
3. Rosenthal AS, Shevach EM: Function of macrophages in antigen recognition by guinea pig T lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes. J Exp Med 138:1194, 1973.
4. Zinkernagel RM, Doherty PC: Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248:701, 1974.
5. Buchmuller Y, Corradin G: Lymphocyte specificity to protein antigens. V. Conformational dependence of activation of cytochrome c-specific T cells. Eur J Immunol 12:412, 1982
6. Heemels MT, Ploegh H: Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 64:463, 1995.
7. York IA, Rock KL: Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14:369, 1996.
8. Koopmann JO, Hämmerling GJ, Momburg F: Generation, intracellular transport and loading of peptides associated with MHC class I molecules. Curr Opin Immunol 9:80, 1997.
9. Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, Engelhard VH: HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen processing. Science 255:1264, 1992.
10. Wei ML, Cresswell P: HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356:443, 1992.
11. Klausner RD, Sitia R: Protein degradation in the endoplasmic reticulum. Cell 62:611, 1990.
12. Hombach J, Pircher H, Tonegawa S, Zinkernagel RM: Strictly transporter of antigen presentation (TAP)-dependent presentation of an immunodominant cytotoxic T lymphocyte epitope in the signal sequence of a virus protein. J Exp Med 182:1615, 1995.
13. Siliciano RF, Soloski MJ: MHC class I-restricted processing of transmembrane proteins. J Immunol 155:2, 1995.
14. Rock KL: A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17:131, 1996.
15. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV: Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361:359, 1993.
16. Schirmbeck R, Melber K, Reimann J: Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. Eur J Immunol 25:1063, 1995.
17. b. Eur J Immunol 23:1802, 1993.
18. Anderson KS, Cresswell P: A role for calnexin (IP90) in the assembly of class II MHC molecules. EMBO J 13: 675, 1994.
19. Pieters J: MHC class II restricted antigen presentation. Curr Opin Immunol 9:89, 1997.
20. Cresswell P: Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 12:259, 1994.
21. Schaiff WT, Hruska KA Jr, McCourt DW, Green M, Schwartz BD: HLA-DR associates with specific stress proteins and is retained in the endoplasmic reticulum in invaraint chain negative cells. J Exp Med 176:657, 1992.
22. Viville S, Neefjes J, Lotteau V, Dierich A, Lemeur M, Ploegh H, Benoist C, Mathis D: Mice lacking the MHC class II-associated invariant chain. Cell 72:635, 1993.
23. Bakke O, Dobberstein B: MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 63:707, 1990.
24. Lotteau V, Teyton L, Péléraux A, Nilsson T, Karlsson L, Schmid SL, Quaranta V, Peterson PA: Intracellular transport of class II molecules directed by invariant chain. Nature 348:600, 1990.
25. Bénaroch P, Yilla M, Raposo G, Ito K, Miwa K, Geuze HJ, Ploegh HL: How MHC class II molecules reach the endocytic pathway. EMBO J 14:37, 1995.
26. Wolf PR, Ploegh HL: How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol 11:267, 1995.
27. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ: Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature 349:669, 1991.
28. Roche PA, Cresswell P: Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 345:615, 1990.
29. Demotz S: DR αβ dimers released from complexes with invariant chain fail to stimulate alloreactive T cell clones. Eur J Immunol 23:2100, 1993.
30. Morkowski S, Goldrath AW, Eastman S, Ramachandra L, Freed DC, Whiteley P, Rudensky AY: T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates. J Exp Med 182:1403, 1995.
31. Zhong G, Castellino F, Romagnoli P, Germain R: Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP). J Exp Med 184:2061, 1996.
32. Ghosh P, Amaya M, Mellins E, Wiley DC: The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378:457, 1995.
33. Bangia N, Watts TH: Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules. Int Immunol 7:1585, 1995.
34. Malcherek G, Gnau V, Jung G, Rammensee HG, Melms A: Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. J Exp Med 181:527, 1995.
35. Sette A, Southwood S, Miller J, Appella E: Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med 181:677, 1995.
36. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P: HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360:474, 1992.
37. Sette A, Ceman S, Kubo RT, Sakaguchi K, Appella E, Hunt DF, Davis TA, Michel H, Shabanowitz J, Rudersdorf R, Grey HM, DeMars R: Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science 258:1801, 1992.
38. Roche PA: HLA-DM: an in vivo facilitator of MHC class II peptide loading. Immunity 3:259, 1995.
39. Weber DA, Evavold BD, Jensen PE: Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 274:618, 1996.
40. Roosnek E, Demotz S, Corradin G, Lanzavecchia A: Kinetics of MHC-antigen complex formation on antigen-presenting cells. J Immunol 140:4079, 1988.
41. Roche PA, Cresswell P: High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J Immunol 144:1849, 1990.
42. Kropshofer H, Hämmerling GJ, Vogt AB: How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today 18:77, 1997.
43. Harding CV, Collins DS, Slot JW, Geuze HJ, Unanue ER: Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells. Cell 64: 393, 1991.
44. Collins D, Unanue ER, Harding CV: Reduction of disulfide bonds within lysosomes is a key step in antigen processing. J Immunol 147:4054, 1991.
45. Barnes KA, Mitchell RN: Detection of functional class II-associated antigen: role of a low density endosomal compartment in antigen processing. J Exp Med 181: 1715, 1995.
46. Barbey C, Watts C, Corradin G: Antigen-processing organelles from DRB1*1101 and DRB1*1104 B cell lines display a differential degradation activity. Eur J Immunol 25:30, 1995.
47. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11:729, 1993.
48. Max H, Halder T, Kropshofer H, Kalbus M, Müller CA, Kalbacher H: Characterization of peptides bound to extracellular and intracellular HLA-DR1 molecules. Hum Immunol 38:193, 1993.
49. Nelson CA, Vidavsky I, Viner NJ, Gross ML, Unanue ER: Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 94:628, 1997.
50. d-restricted hen egg lysozyme determinant 107-116. Eur J Immunol 26:1656, 1996.
51. Cresswell P: Intracellular class II HLA antigens are accessible to transferrin-neuraminidase conjugates internalized by receptor-mediated endocytosis. Proc Natl Acad Sci USA 82:8188, 1985.
52. Amigorena S, Drake JR, Webster P, Mellman I: Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes. Nature 369:113, 1994.
53. Qiu Y, Xu X, Wandinger-Ness A, Dalke DP, Pierce SK: Separation of subcellular compartments containing dis-tinct functional forms of MHC class II. J Cell Biol 125:595, 1994
54. Rudensky AY, Marie M, Eastman S, Shoemaker L, DeRoos PC, Blum JS: Intracellular assembly and transport of endogenous peptide-MHC class II complexes. Immunity 1:585, 1995.
55. Tulp A, Verwoerd D, Dobberstein B, Ploegh HL, Pieters J: Isolation and characterization of the intracellular MHC class II compartment. Nature 369:120, 1994.
56. West MA, Lucocq JM, Watts C: Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells. Nature 369:147, 1994.
57. Castellino F, Germain RN: Extensive trafficking of MHC class II-invariant chain complexes in the endocytic pathway and appearance of peptide-loaded class II in multiple compartments. Immunity 2:73, 1995.
58. Wubbolts R, Fernandez-Borja M, Oomen L, Verwoerd D, Janssen H, Calafat J, Tulp A, Dusseljee S, Neefjes J: Direct vesicular transport of MHC class II molecules from lysosomal structures to the cell surface. J Cell Biol 135:611, 1996.
59. Germain RN, Rinker AG Jr: Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 363:725, 1993.
60. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27, 1993.
61. Sijts AJAM, Neissig A, Neefjes J, Pamer EG: Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. J Immunol 156: 685, 1995.
62. Pinet V, Malnati MS, Long EO: Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen. J Immunol 152:4852, 1994.
63. Pinet V, Vergelli M, Martin R, Bakke O, Long EO: Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 375:603, 1995.
64. Swier K, Miller J: Invariant chain-independent antigen presentation depends primarily upon the pool of newly synthesized MHC class II molecules. J Immunol 155: 1851, 1995.
65. Demotz S, Péléraux A: DR1-restricted determinants from the fusion protein of measles virus processed following two distinct pathways. Mol Immunol 33:387, 1996.
66. Pierre P, Denzin LK, Hammond C, Drake JR, Amigorena S, Cresswell P, Mellman I: HLA-DM is localized to conventional and unconventional MHC class II-containing endocytic compartments. Immunity 4:229, 1996.
67. Lanzavecchia A, Reid PA, Watts C: Irreversible association of peptides with class II MHC molecules in living cells. Nature 357:249, 1992.
68. Pedrazzini T, Sette A, Albertson M, Grey HM: Free ligand-induced dissociation of MHC-antigen complexes. J Immunol 146:3496, 1991.
69. Reay PA, Wettstein DA, Davis MM: pH dependence and exchange of high and low responder peptides binding to a class II MHC molecule. EMBO J 11:2829, 1992.
70. Nelson CA, Petzold SJ, Unanue ER: Peptides determine the lifespan of MHC class II molecules in the antigen- presenting cell. Nature 371:250, 1994.
71. Long EO, LaVaute T, Pinet V, Jaraquemada D: Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide. J Immunol 153:1487, 1994.
72. Nijenhuis M, Neefjes J: Early events in the assembly of major histocompatibility complex class II heterotrimers from their free subunits. Eur J Immunol 24:247, 1994.
73. Newcomb JR, Cresswell P: Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated αβ dimers. J Immunol 150:499, 1993.
74. Bijlmakers MJJE, Benaroch P, Ploegh HL: Assembly of HLA DR1 molecules translated in vitro: binding of peptide in the endoplasmic reticulum precludes association with invariant chain. EMBO J 13:2699, 1994.
75. Hedley ML, Urban RG, Strominger JL: Assembly and peptide binding of major histocompatibility complex class II heterodimers in an in vitro translation system. Proc Natl Acad Sci USA 91:10479, 1994.
76. Bartido SM, Diment S, Reiss CS: Processing of a viral glycoprotein in the endoplasmic reticulum for class II presentation. Eur J Immunol 25:2211, 1995.
77. + cytotoxic T cell clones. J Immunol 142:2847, 1989.
78. k . Proc Natl Acad Sci USA 89:7380, 1992.
79. Dunn WA Jr: Autophagy and related mechanisms of lysosome-mediated protein degradation. Trends Cell Biol 4:139, 1994.
80. Terlecky SR, Dice JF: Polypeptide import and degradation by isolated lysosomes. J Biol Chem 268:23490, 1993.
81. Demotz S, Lanzavecchia A, Eisel U, Niemann H, Widmann C, Corradin G: Delineation of several DR-restricted tetanus toxin T cell epitopes. J Immunol 142: 394, 1989.
82. Demotz S, Matricardi P, Lanzavecchia A, Corradin G: A novel and simple procedure for determining T cell epitopes in protein antigens. J Immunol Methods 122: 67, 1989.
83. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A: Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19:2237, 1989.
84. Sinigaglia F, Guttinger M, Kilgus J, Moran DM, Matile H, Etlinger HM, Trzeciak A, Gillesen D, Pink JR: A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336:778, 1988.
85. Mitchison NA: The carrier effect in the secondary response to hapten-protein conjugates. I. Measurement of the effect with transferred cells and objection to the local environment hypothesis. Eur J Immunol 1:10, 1971.
86. Herzenberg LA, Tokuhisa T, Herzenberg LA: Carrier-priming leads to hapten-specific suppression. Nature 285:664, 1980.
87. Etlinger HM, Gillissen D, Lahm HW, Matile H, Sconfeld HJ, Trzeciak A: Use of prior vaccination for the development of new vaccines. Science 249:423, 1990.
88. Valmori D, Pessi A, Bianchi E, Corradin G: Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J Immunol 149:717, 1992.
89. Tam JP: Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 85:5409, 1988.
90. Tam JP, Clvijo P, Lu YA, Nussenzweig V, Nussenzweig R, Zavala F: Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med 82:299, 1990.
91. Pessi A, Valmori D, Migliorini P, Tougne C, Bianchi E, Lambert P-H, Corradin G, Del Giudice G: Lack of H-2 restriction of the Plasmodium falciparum (NANP) sequence as multiple peptide antigen. Eur J Immunol 21:2273, 1991.
92. Wang R, Charonenvit Y, Corradin G, Porrozzi R, Hunter RL, Glenn G, Alving CR, Church P, Hoffman SL: Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J Immunol 154:2784, 1995.
93. Herrera S, de Plata C, Gonzalez JM, Perlasa BL, Bettens F, Gorradin G, Arévalo-Herrera M: Antigenicity and immunogenicity of multiple antigen peptides containing P. vivax CS epitopes in Aotus monkeys. Paras Immunol 16:161, 1997.
94. Kumar A, Arora R, Kaur P, Chauhan VS, Sharma P: "Universal" T helper cell determinants enhance immunogenicity of a Plasmodium falciparum merozoite surface antigen peptide. J Immunol 148:1499, 1992.
95. Ho PC, Mutch DA, Winkel KD, Saul AJ, Jones GL, Doran TJ, Rzepczyk CM: Identification of two promiscuous T cell epitopes from tetanus toxin. Eur J Immunol 20:477, 1990.
96. Reece JC, Geysen HM, Rodda SJ: Mapping the major human T cell epitopes of tetanus toxin. J Immunol 151:6175, 1993.
97. Grilliot D, Valmori D, Lambert PH, Corradin G, Del Giudice G: Presentation of T-cell epitopes assembled as multiple antigen peptides to murine and human T lymphocytes. Infect Immun 61:3064, 1993.
98. Astori M, Kraehenbuhl JP: Recombinant fusion peptides containing single or multiple repeats of an ubiquitous T-helper epitope are highly immunogenic. Mol Immunol 13:1017, 1996.
99. Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH, Kaslow D: Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein. 1 in Aotus monkeys. Mol Med 1:325, 1995.
100. Widmann C, Romero P, Maryanski JL, Corradin G, Valmori D: T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J Immunol Methods 155:95, 1992.
101. Valmori D, Romero J, Men Y, Maryanski JM, Romero P, Corradin G: Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant: further enhancement by pre-injection of IFA alone. Eur J Immunol 25:1458, 1994.
102. + T-cell protective immunity induced by immunization with Plasmodium berghei CS protein derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. Immunol Lett 46:199, 1995.
103. Franke ED, Corradin G, Hoffman SL: Induction of protective CTL responses against Plasmodium yoelii circumsporozoite protein by immunization with peptides. J Immunol (in press).
104. Brander C, Pichler WJ, Corradin G: Identification of HIV protein derived cytotoxic T lymphocyte (CTL) epitopes for their possible use as synthetic vaccine. Clin Exp Immunol 101:107, 1995.
105. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R, et al.: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95:341, 1995.
106. Yu Z, Healy F, Valmori D, Escobar P, Corradin G, Mach JP: Peptide-antibody conjugates for tumor therapy: a MHC-class II-restricted tetanus toxin peptide coupled to an anti-Ig light chain antibody can induce cytotoxic lysis of a human B-cell lymphoma by specific CD4 T cells. Int J Cancer 56:244, 1994.